IMW 2021 | Real-world data: treatment pathways for myeloma patients in France
Aurore Perrot
• 9 Sep 2021
Aurore Perrot, MD, of Université de Toulouse, UPS, Service d’Hématologie, Toulouse, France, gives an overview of a real-world study investigating treatment pathways for patients with myeloma in France. The study has followed more than 40,000 patients since 2014, and is reporting on data from patients who initiated first-line therapy in 2014 and 2015. High attrition was observed, especially among the elderly population. Dr Perrot comments on the need to give therapy as early as possible, and describes how the therapeutic landscape is rapidly changing, highlighting changes in the use of daratumumab. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
